Form 8-K HALOZYME THERAPEUTICS, For: Nov 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Halozyme Therapeutics (HALO) Tops Q3 EPS by 6c; Raises Outlook
November 2, 2020 4:37 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.25, $0.06 better than the analyst estimate of $0.19. Revenue for the quarter came in at $65.3 million versus the consensus estimate of $60.9 million.
GUIDANCE:
Halozyme Therapeutics sees FY2020 EPS of $0.80-$0.85, versus the consensus of $0.69.... More
